KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Sep 2025 value amounting to $4.4 million.

  • Acadia Pharmaceuticals' Net Cash Flow rose 123.01% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.6 million, marking a year-over-year increase of 72.64%. This contributed to the annual value of $134.0 million for FY2024, which is 81.54% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Net Cash Flow stood at $4.4 million, which was down 88.10% from $36.6 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Net Cash Flow ranged from a high of $176.1 million in Q1 2023 and a low of -$180.6 million during Q2 2023.
  • In the last 3 years, Acadia Pharmaceuticals' Net Cash Flow had a median value of $4.4 million in 2025 and averaged $13.4 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Net Cash Flow surged by 366.79% in 2022 and then plummeted by 733.51% in 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Net Cash Flow (Quarterly) stood at $52.8 million in 2021, then crashed by 175.74% to -$40.0 million in 2022, then surged by 326.26% to $90.5 million in 2023, then skyrocketed by 81.82% to $164.5 million in 2024, then soared by 123.01% to $4.4 million in 2025.
  • Its Net Cash Flow stands at $4.4 million for Q3 2025, versus $36.6 million for Q2 2025 and -$101.9 million for Q1 2025.